Clever Leaves (CLVR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CLVR vs. AMPE, EFTR, HSTO, ONCSQ, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, and ALVOWShould you be buying Clever Leaves stock or one of its competitors? The main competitors of Clever Leaves include Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), OncoSec Medical (ONCSQ), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), and Alvotech (ALVOW). These companies are all part of the "pharmaceutical products" industry. Clever Leaves vs. Its Competitors Ampio Pharmaceuticals eFFECTOR Therapeutics Histogen OncoSec Medical PaxMedica 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Clever Leaves (NASDAQ:CLVR) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Does the media favor CLVR or AMPE? In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Clever Leaves Neutral Ampio Pharmaceuticals Neutral Which has more volatility and risk, CLVR or AMPE? Clever Leaves has a beta of 3440.04, meaning that its share price is 343,904% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 4.76, meaning that its share price is 376% more volatile than the S&P 500. Which has better earnings and valuation, CLVR or AMPE? Ampio Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClever Leaves$17.42M0.00-$17.90M-$11.31N/AAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00 Do insiders & institutionals hold more shares of CLVR or AMPE? 6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CLVR or AMPE more profitable? Company Net Margins Return on Equity Return on Assets Clever LeavesN/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A SummaryClever Leaves beats Ampio Pharmaceuticals on 5 of the 7 factors compared between the two stocks. Get Clever Leaves News Delivered to You Automatically Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLVR vs. The Competition Export to ExcelMetricClever LeavesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$785.26M$5.48B$9.54BDividend YieldN/A4.84%4.73%4.09%P/E Ratio0.001.3728.8623.83Price / SalesN/A25.68371.7266.14Price / CashN/A19.5635.4557.96Price / BookN/A6.688.275.54Net Income-$17.90M-$3.67M$3.25B$259.28M Clever Leaves Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLVRClever LeavesN/AN/AN/AN/A$1K$17.42M0.00560AMPEAmpio PharmaceuticalsN/A$0.00+3.7%N/A+1,350.0%$3KN/A0.0020Gap UpEFTReFFECTOR Therapeutics0.0972 of 5 stars$0.00+200.0%N/A-99.5%$3KN/A0.0010HSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040PXMDPaxMedicaN/AN/AN/AN/A$1KN/A0.002ATNFW180 Life SciencesN/A$0.01-1.9%N/A+18.6%$0.00N/A0.007News CoveragePositive NewsGap UpHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.13+0.7%N/AN/A$0.00$106.21K0.0040Positive NewsGap DownALVOWAlvotechN/A$1.94-27.1%N/A-47.5%$0.00$585.60M0.004Positive NewsGap Down Related Companies and Tools Related Companies AMPE Alternatives EFTR Alternatives HSTO Alternatives ONCSQ Alternatives PXMD Alternatives ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives AIMDW Alternatives ALVOW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLVR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clever Leaves Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clever Leaves With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
